|
Jun 26
|
European Equities Traded in the US as American Depositary Receipts Higher in Thursday Trading
|
|
Jun 12
|
High Growth Tech Stocks In Europe To Watch June 2025
|
|
Jun 2
|
GRFS vs. STVN: Which Stock Is the Better Value Option?
|
|
May 30
|
US court proceeds with Grifols defamation case against Gotham City, but narrows scope
|
|
May 28
|
ADMA Biologics vs. Grifols: Which Plasma Therapy Stock Is the Better Buy?
|
|
Jan 2
|
Exploring Three High Growth Tech Stocks For Future Potential
|
|
Aug 29
|
Brookfield Courts Sovereign Funds to Join Grifols Takeover Bid
|
|
Aug 26
|
This Reviled Pharmaceutical Firm Holds Promise of a Healthier Future
|
|
Jul 29
|
Grifols receives expanded XEMBIFY® (immune globulin subcutaneous human-klhw) label in U.S., strengthening its Ig portfolio for patients
|
|
Jun 18
|
Grifols completes sale of a 20% equity stake in SRAAS and forges strategic alliance with Haier Group
|
|
Jun 17
|
Biotest wins FDA approval for plasma protein therapy
|
|
Jun 17
|
Grifols prepares for late-stage plans with plasma-derived medicines in 2024
|
|
Jun 17
|
Grifols’ Biotest receives FDA approval for innovative Yimmugo® immunoglobulin to treat primary immunodeficiencies
|
|
May 9
|
Short Seller Gains on Grifols Bet That Tripped Elliott Spinout
|
|
Apr 14
|
Spanish drug maker Grifols will bring in independent directors, chairman tells newspaper
|
|
Mar 22
|
Grifols Drops as Regulator Finds ‘Relevant Deficiencies’
|
|
Jan 15
|
Here's Why Grifols (GRFS) is Poised for a Turnaround After Losing -31.55% in 4 Weeks
|
|
Jan 14
|
Grifols Says Haier Has Offered Reassurance on China Deal
|
|
Jan 14
|
Grifols says Haier Group still OK to buy stake in Shanghai RAAS
|
|
Jan 12
|
Grifols shares suffer worst week on record after short-seller report
|